ICAM1 and myeloid sarcoma: These findings are in accord with previous reports that MSCs both attenuated BBB/BSCB damage in a variety of animal models of neurologic disease other than MS/EA [56–61], and down-regulated ICAM-1 expression in oxygen-glucose deprived (OGD)/re-oxygenated bEND.3 cells [57], a virally-transformed brain capillary hemangioma cell line [73].